CION Ameerpet
Treatment · Reviewed by CION Oncologists · NABH Accredited
Targeted Therapy for Advanced Endometrial Cancer
Targeted therapy is not a single treatment, which is the first thing to understand about it. It is a set of drug classes, each acting on a specific mechanism a tumour depends on — and which of them you can be offered depends on what testing shows about your tumour rather than on what stage you are. That is why molecular testing is the gateway to this whole area, and why a tumour that has not been tested has options that nobody has looked for. This page explains the classes in plain terms, what determines access to each, and what the side effects genuinely involve — because they differ from chemotherapy in ways worth knowing in advance.
- Not one drug but several classes — each acting on a different mechanism
- Molecular testing is the gateway — it determines what you can access
- Side effects are continuous, not cyclical — a real difference from chemotherapy
- This area has changed fast — material from a few years ago is out of date
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Classes and What They Do
Described by mechanism rather than by brand or molecule name. Your oncologist will name the specific agents appropriate to your situation.
| Class | How it works and where it fits |
|---|---|
| Anti-angiogenic agents | Tumours need to build their own blood supply to grow beyond a small size. This class blocks the signalling that drives new vessel formation, effectively starving the tumour of supply. Used in advanced disease, frequently in combination with immune checkpoint inhibition. |
| Immune checkpoint inhibition | Not strictly targeted therapy but inseparable from it here, since the two are often combined. It releases a brake on the immune system so it can recognise the tumour. Particularly effective in mismatch repair deficient tumours. See immunotherapy. |
| The two in combination | A combination of an anti-angiogenic agent with checkpoint inhibition became an important option in advanced endometrial cancer, particularly for mismatch repair proficient tumours which respond less well to checkpoint inhibition alone. |
| HER2-directed treatment | A minority of endometrial cancers, principally uterine serous carcinoma, overexpress HER2 — the same target familiar from breast cancer. Where testing shows this, HER2-directed treatment becomes an option. It is a reason to ask for HER2 testing in serous disease. See serous carcinoma. |
| Antibody-drug conjugates | An antibody that recognises a marker on the tumour cell, carrying a cytotoxic payload delivered directly to it. A newer approach in this disease and an area of active development. |
| Hormonal treatment | Often grouped separately and worth naming here, since it targets the oestrogen dependence of low-grade endometrioid tumours and is well tolerated. See hormone therapy. |
What you can be offered depends on your tumour’s profile, not just its stage. If your report does not state mismatch repair status, ask for it — it can nearly always be done on the stored tissue block, and it opens or closes entire lines of treatment. See MMR and MSI testing.
Did You Know? The reason molecular testing matters so much in advanced endometrial cancer is that it does not merely refine the plan — it determines which plans exist. A mismatch repair deficient tumour has systemic options that a proficient one does not, and the reverse is also true: specific combinations were developed precisely for tumours that are mismatch repair proficient. A tumour that has never been characterised sits outside both conversations. This is why, if you have advanced or recurrent disease and your original pathology report says nothing about mismatch repair or p53, the single most useful thing you can do is ask for that testing to be performed on the stored tissue. It can nearly always be done retrospectively. Sources: NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; ESMO Clinical Practice Guidelines on endometrial cancer.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Where This Fits in Treatment
Targeted therapy belongs to advanced and recurrent disease. It is not part of the treatment for early endometrial cancer.
- Not used for early disease. Early endometrial cancer confined to the uterus is treated by surgery, with radiotherapy for some women. Targeted therapy has no role there, and its absence from your plan is correct rather than an omission. See treatment after surgery.
- Chemotherapy usually comes first in advanced disease. Combination chemotherapy remains the standard initial systemic treatment for advanced or metastatic endometrial cancer, frequently now with checkpoint inhibition added. See chemotherapy.
- Targeted therapy is central at progression. When disease progresses after initial chemotherapy, this is where the targeted classes come into their own, and where molecular profile determines the choice. See treating recurrence.
- Treatment continues while it works. Unlike chemotherapy, which runs for a set number of cycles, targeted treatment is generally continued for as long as it is controlling the disease and being tolerated. That changes how you plan your life around it.
- Clinical trials are worth asking about. This is a fast-moving area and trial access is a legitimate part of the conversation rather than a last resort. Ask what is open and whether you would be eligible.
Want Your Systemic Options Reviewed?
Molecular testing completed if it was never done, and your case taken to the tumour board.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Untested Means Unconsidered
A tumour with no molecular profile sits outside every conversation these treatments belong to.
Side Effects, Honestly
Different in character from chemotherapy — usually less intense at any moment, and continuous rather than coming in waves.
Raised blood pressure
Common with the anti-angiogenic class and a direct consequence of how it works. It is monitored actively and treated with ordinary blood pressure medication rather than by stopping treatment. You will likely be asked to check your own pressure at home, and doing so reliably genuinely matters.
Fatigue that does not come in cycles
Chemotherapy fatigue comes and goes around each cycle; this tends to be a steady background level. That has practical implications for work and family planning, and it is worth discussing dose adjustment rather than simply enduring it. See managing fatigue.
Diarrhoea
Common and manageable, and it needs reporting early rather than tolerating. Untreated it causes dehydration and weight loss which then compromise the treatment itself. There are effective medications and dose adjustments.
Thyroid changes
The thyroid is affected by several of these treatments, and underactivity is common. It is picked up on routine blood tests and treated straightforwardly with replacement. It matters because untreated it worsens fatigue substantially and is easily attributed to the cancer instead.
Hand-foot skin reaction
Soreness, redness and thickening of the palms and soles, which can make walking and everyday tasks uncomfortable. Preventive skin care from the outset, comfortable footwear and early reporting all help considerably, and dose modification is used where it becomes limiting.
Want Your Options Reviewed by a Board?
Bring your reports. Molecular testing completed if needed, and every systemic option considered. The opinion is free.
Questions Worth Asking
Five that produce a specific answer.
- “What is my tumour’s molecular profile?” Mismatch repair status above all, and HER2 status if you have serous carcinoma. If either has not been done, ask whether it can be done on the stored tissue.
- “What are my options in order, and what comes after this one?” Knowing there is a next line, and what it is, changes how the current one feels. It is a reasonable thing to ask and a good oncologist will answer it.
- “What is the intent of this treatment?” Control of the disease, extension of time, relief of symptoms — ask plainly. Clear answers are more useful than optimistic ones and they let you plan.
- “What am I monitoring at home?” Blood pressure in particular. Knowing what to record and at what threshold to ring converts a vague anxiety into a task.
- “Is there a trial I would be eligible for?” A legitimate question at any point, not only when other options are exhausted. See second opinion.
Why This Area Needs Current Practice
Systemic treatment for advanced endometrial cancer has changed substantially in a short time, and material from a few years ago is genuinely out of date.
MMR / MSI testing as standard
Tumour board for every diagnosis
Slides reviewed, not just the summary line
Costs explained before you commit
Psycho-oncology and nutrition on the team
Second opinions welcomed, not resented
Take The Next Step
Ask for the Profile First
It is the gateway question — it determines which treatments are even on the table.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Targeted Therapy — Frequently Asked Questions
What is targeted therapy and how is it different from chemotherapy?
Chemotherapy acts on rapidly dividing cells generally, which is why it affects hair, blood counts and the lining of the gut alongside the tumour. Targeted therapy acts on a specific mechanism the tumour depends on — the signalling that lets it build a blood supply, a particular protein on its surface, or a pathway it relies on to grow. Because the mechanism is specific, the treatment is only useful where the tumour actually depends on it, which is why molecular testing determines what can be offered. The side effects are also different: usually less intense at any given moment, but continuous rather than arriving in cycles.
Why does my tumour need molecular testing before this?
Because the testing determines which options exist rather than merely refining a choice among them. Mismatch repair status is the principal gateway: deficient tumours have systemic options that proficient ones do not, and specific combinations were developed precisely for proficient tumours. In uterine serous carcinoma, HER2 testing identifies a further option. A tumour that has never been profiled sits outside all of these conversations. If your report says nothing about mismatch repair or p53, ask for the testing to be done — it can nearly always be performed on stored tissue from your original biopsy or operation.
Is targeted therapy given for early endometrial cancer?
No. Early endometrial cancer confined to the uterus is treated with surgery, and some women have radiotherapy afterwards depending on their risk factors. Targeted therapy belongs to advanced and recurrent disease. If you have early-stage disease and are wondering why these treatments are not part of your plan, its absence is correct rather than an omission — they have not been shown to help in that setting and they carry real side effects. What does matter in early disease is that molecular classification is done, because it can reduce as well as increase the treatment recommended.
What side effects should I expect?
They differ by class, and for the anti-angiogenic agents the common ones are raised blood pressure, steady fatigue, diarrhoea, thyroid underactivity and soreness of the palms and soles. Two things are worth knowing in advance. First, the fatigue tends to be a constant background rather than a cycle, which has different practical implications for work and family life. Second, most of these are managed by monitoring and dose adjustment rather than by stopping — blood pressure with ordinary medication, thyroid changes with replacement, diarrhoea with early treatment. Reporting them early is what keeps treatment going.
How long does treatment continue?
Generally for as long as it is controlling the disease and you are tolerating it, which is a real difference from chemotherapy given as a fixed number of cycles. That has practical consequences: it is a treatment you build a life around rather than get through, which makes managing side effects properly more important than enduring them. Dose reduction is a normal part of this and is not a failure. Treatment is reviewed with scans at intervals, and if the disease progresses, the conversation moves to what comes next — which is a question worth asking before you need the answer.
Medical disclaimer: This page describes classes of targeted treatment for advanced endometrial cancer by mechanism, reviewed by a CION oncologist. It does not name individual drugs, and it is not a substitute for individual medical advice. Which treatments are appropriate depends on your tumour's molecular characteristics, previous treatment and general health, and should be decided with your medical oncologist following multidisciplinary discussion.